Myocardial damage assessed by late gadolinium enhancement on cardiovascular magnetic resonance imaging in cancer patients treated with anthracyclines and/or trastuzumab
| Autor: | Prabhjot S. Nijjar, Matthew Hooks, Pal Satyajit Singh Athwal, Ko Hsuan Amy Chen, Anne H. Blaes, Osama Okasha, Pratik S. Velangi, Kalpit Modi, Stephanie Joppa, Chetan Shenoy |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Anthracycline Ischemia Cardiomyopathy Contrast Media Magnetic Resonance Imaging Cine Gadolinium 030204 cardiovascular system & hematology 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Linear gingival erythema Predictive Value of Tests Trastuzumab Neoplasms Internal medicine medicine Humans Anthracyclines Radiology Nuclear Medicine and imaging cardiovascular diseases skin and connective tissue diseases Cardiotoxicity medicine.diagnostic_test business.industry Cancer Magnetic resonance imaging Original Articles General Medicine medicine.disease Magnetic Resonance Imaging embryonic structures Cardiology Cardiomyopathies Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Eur Heart J Cardiovasc Imaging |
| ISSN: | 2047-2412 2047-2404 |
| Popis: | Aims In cancer patients with cardiomyopathy related to anthracyclines and/or trastuzumab, data regarding late gadolinium enhancement (LGE) on cardiovascular magnetic resonance imaging are confusing. The prevalence ranges from 0% to 30% and the patterns are ill-defined. Whether treatment with anthracyclines and/or trastuzumab is associated with LGE is unclear. We aimed to investigate these topics in a large cohort of consecutive cancer patients with suspected cardiotoxicity from anthracyclines and/or trastuzumab. Methods and results We studied 298 patients, analysed the prevalence, patterns, and correlates of LGE, and determined their causes. We compared the findings with those from 100 age-matched cancer patients who received neither anthracyclines nor trastuzumab. Amongst those who received anthracyclines and/or trastuzumab, 31 (10.4%) had LGE. It had a wide range of extent (3.9–34.7%) and locations. An ischaemic pattern was present in 20/31 (64.5%) patients. There was an alternative explanation for the non-ischaemic LGE in 7/11 (63.6%) patients. In the age-matched patients who received neither anthracyclines nor trastuzumab, the prevalence of LGE was higher at 27.0%, while the extent of LGE and the proportion with ischaemic pattern were not different. Conclusion LGE was present in only a minority. Its patterns and locations did not fit into a single unique profile. It had alternative explanations in virtually all cases. Finally, LGE was also present in cancer patients who received neither anthracyclines nor trastuzumab. Therefore, treatment with anthracyclines and/or trastuzumab is unlikely to be associated with LGE. The absence of LGE can help distinguish anthracycline- and/or trastuzumab-related cardiomyopathy from unrelated cardiomyopathies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|